Top 5 Stocks to Buy Now
→ A huge SpaceX error just led one stock to 3X move! (From InvestPub) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£132.34 +80.00 (+0.61%)
As of 06/19/2026 12:21 PM Eastern
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings
Sell
1
Hold
0
Buy
5

Based on 6 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a sell rating, and 5 have given a buy rating for AZN.

Consensus Price Target

£153.33
According to the 6 analysts' twelve-month price targets for AstraZeneca, the average price target is £153.33. The highest price target for AZN is £180, while the lowest price target for AZN is £115. The average price target represents a forecasted upside of 15.86% from the current price of £132.34.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
6/20/25 to 6/20/26		1 Month Ago
5/21/25 to 5/21/26		3 Months Ago
3/22/25 to 3/22/26		1 Year Ago
6/20/24 to 6/20/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£153.33£153.33£145.83GBX 6,303.50
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical Companies
Consensus Rating Score
2.67
2.29
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
6/11/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Reiterated RatingSell£115 ➝ £115-13.55%
6/9/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy£180 ➝ £180+32.37%
4/10/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
 Boost TargetBuy£170 ➝ £180+16.94%
1/27/2026
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy£145 ➝ £160+17.94%
1/16/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/15/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:17 PM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 19, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • The current stock price is around £134.96, which reflects a strong market position and investor confidence in the company's future growth.
  • AstraZeneca PLC has a robust pipeline of innovative medicines, particularly in oncology and respiratory treatments, which could lead to significant revenue growth.
  • The company has a low beta of 0.17, indicating that its stock is less volatile compared to the market, making it a potentially safer investment during market fluctuations.
  • With a market cap of £210.69 billion, AstraZeneca PLC is well-established, providing stability and a strong foundation for future expansion.
  • The PEG ratio of 0.86 suggests that the stock may be undervalued relative to its earnings growth potential, making it an attractive option for growth-oriented investors.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • The price-to-earnings ratio of 22.58 may indicate that the stock is relatively expensive compared to its earnings, which could deter value-focused investors.
  • Insider selling activity, such as the recent sale of shares by Nazneen Rahman, may raise concerns about the company's future prospects and insider confidence.
  • Despite its strong market presence, AstraZeneca PLC faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability.
  • The company operates in a highly regulated environment, and any changes in regulations or approval processes could adversely affect its operations and product launches.
  • Market sentiment can be influenced by broader economic conditions, and AstraZeneca PLC may be affected by economic downturns or shifts in healthcare spending.

AZN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £153.33, with a high forecast of £180 and a low forecast of £115.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 15.86% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, and Jefferies Financial Group in the past 90 days.

Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how AZN compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations


This page (LON:AZN) was last updated on 6/20/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
An Elon Musk Fan's Warning About SPCX
Jon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel